GlassScriptPhysician profile
Andrea M Rossi
NPI 1932321635
$103,049.67
in general payments reported to CMS, 2019-2025
71 companies · $19K in 2025
The $19K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,206 · 2020: $9,932 · 2021: $28K · 2022: $21K · 2023: $8,455 · 2024: $15K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $10K · Consulting Fee: $5,105 · Travel and Lodging: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,762.50 |
| Food and Beverage | $10,361.36 |
| Consulting Fee | $5,105.00 |
| Travel and Lodging | $122.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $49,236.48 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $15,942.07 | 2019-2025 | |
| Allergan, INC. | $10,858.22 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $6,991.02 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $4,979.48 | 2022 | |
| Novartis Pharmaceuticals Corporation | $2,268.41 | 2019-2025 | |
| Emd Serono, INC. | $2,003.24 | 2019-2025 | Mavenclad |
| Ucb, INC. | $1,892.47 | 2020-2025 | Zilbrysq, Rystiggo, Briviact |
| Celgene Corporation | $901.10 | 2021-2025 | Zeposia |
| Biogen, INC. | $622.24 | 2019-2025 | Tysabri, Vumerity |
| Amgen INC. | $509.23 | 2019-2025 | Uplizna |
| Genzyme Corporation | $466.02 | 2019-2025 | |
| Tg Therapeutics, INC. | $455.57 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $356.46 | 2019-2024 | Ultomiris |
| Neurocrine Biosciences, INC. | $318.91 | 2019-2025 | Ingrezza, Ongentys |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Rossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.